📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Cohance Lifesciences Revises FY26 Revenue Outlook to Double-Digit Decline; Q3 CDMO Down 27%
Cohance Lifesciences reported a challenging Q3 FY26, with Pharma CDMO revenue declining 27% YoY due to inventory destocking and patent expiries in key molecules. Consequently, the company has revised its FY26 revenue guidance to an early-to-mid double-digit decline, citing a transition year impacted by customer-led timing delays. Despite these headwinds, the company maintains a robust pipeline with 9 Phase 3 programs and expects a recovery in FY27 driven by new product launches. Management is also investing $10 million in US-based capacity to strengthen its Antibody-Drug Conjugate (ADC) platform.
Key Highlights
Revised FY26 revenue outlook downward to an early-to-mid double-digit decline.
Pharma CDMO revenue fell 27% YoY in Q3 FY26, though adjusted growth was 7% excluding destocking.
Currently supporting 9 Phase 3 molecules, with 4 expected to move into commercial supply in FY27.
Investing $10 million in a cGMP US-based expansion for ADC supply capability by end of FY27.
Nacharam facility remediation is ongoing following a USFDA warning letter, with production resumed for non-US markets.
💼 Action for Investors
Investors should remain cautious as the significant guidance cut suggests near-term earnings pressure and execution risks. Monitor the successful commercialization of the four Phase 3 assets in FY27 and the resolution of the USFDA warning letter as key recovery indicators.
Cohance Lifesciences Q3 Revenue Drops 19.5%; FY26 Guidance Revised to Double-Digit Decline
Cohance Lifesciences reported a weak Q3 FY26 with revenue declining 19.5% YoY to ₹5,446 mn and Adjusted PAT plunging 87.3% to ₹211 mn. The company has revised its FY26 revenue guidance from a flat outlook to an early-to-mid double-digit decline, citing inventory normalization and regulatory disruptions. Despite the downturn, gross margins improved to 72.8% for 9M FY26, and the company maintains a healthy cash position of ₹4.32 Bn. Management views FY26 as a transition year and expects a return to growth in FY27.
Key Highlights
9M FY26 Adjusted EBITDA fell 43.4% YoY to ₹3,477 mn, with margins compressing from 34.8% to 21.1%.
Pharma CDMO revenue for Q3 fell to ₹2,105 mn, impacted by customer-led inventory normalization and payload timing.
Regulatory issues at the Nacharam plant led to a Warning Letter and approximately ₹55 crore in shipment deferrals.
Company generated ₹1.75 Bn in free cash flow during 9M FY26 despite significant operational headwinds.
Revised FY26 outlook projects a double-digit revenue decline, shifting the recovery timeline to FY27.
💼 Action for Investors
Investors should exercise caution as the company navigates a transition phase and regulatory hurdles at its Nacharam site. Monitor the execution of the commercial pipeline and the anticipated recovery in the CDMO segment in FY27.
Cohance Lifesciences Q3 FY26 Consolidated Net Profit Drops 81% YoY to ₹29.02 Crore
Cohance Lifesciences (formerly Suven Pharmaceuticals) reported a weak set of numbers for Q3 FY26, with consolidated revenue falling 19.5% YoY to ₹544.55 crore. Net profit saw a massive decline of 81%, dropping to ₹29.02 crore from a restated ₹153.48 crore in the previous year's corresponding quarter. The results are heavily impacted by the restatement of accounts following the merger of Casper Pharma and the erstwhile Cohance Lifesciences. Additionally, an exceptional cost of ₹4.86 crore was recorded due to new labor code implementations.
Key Highlights
Consolidated Revenue from operations fell to ₹544.55 crore in Q3 FY26 from ₹676.23 crore (restated) in Q3 FY25.
Consolidated Net Profit plummeted 81% YoY to ₹29.02 crore compared to ₹153.48 crore in the year-ago period.
Consolidated EPS for the quarter stood at ₹0.96, down significantly from ₹4.02 in Q3 FY25.
Total expenses remained high at ₹505.25 crore despite the drop in revenue, impacting operating margins.
Exceptional items for the quarter included a ₹4.86 crore charge for the implementation of new labor codes.
💼 Action for Investors
Investors should be cautious as the post-merger entity is showing significant margin pressure and a sharp decline in profitability. It is advisable to wait for management commentary on merger synergies and recovery timelines in the CDMO segment before making new entries.
Cohance Lifesciences Receives USFDA Warning Letter for Hyderabad Unit; Financial Impact <2% Revenue
Cohance Lifesciences (formerly Suven Pharmaceuticals) has received a formal Warning Letter from the USFDA for its Finished Dosage Formulations (FDF Unit-I) facility in Nacharam, Hyderabad. This follows an August 2025 inspection that resulted in six observations and an 'Official Action Indicated' (OAI) classification. The company noted that the facility's contribution to consolidated FY25 revenue is less than 2%, with an EBITDA impact of less than 1%. Management is currently preparing a comprehensive response and implementing corrective actions to address the regulator's concerns.
Key Highlights
USFDA issued a Warning Letter for the FDF Unit-I facility following an inspection in August 2025.
The facility was previously classified as Official Action Indicated (OAI) based on six observations.
Financial impact is limited, with the unit contributing less than 2% of consolidated FY25 revenues.
EBITDA contribution from the affected facility is less than 1% of the company's total.
Company is proactively engaging with the USFDA to submit a response within stipulated timelines.
💼 Action for Investors
While the immediate financial impact is minimal, investors should monitor the resolution timeline as a Warning Letter can stall new product approvals from this site. Watch for management updates regarding the successful implementation of corrective actions and the lifting of the OAI status.
Cohance Lifesciences Receives USFDA Warning Letter for Nacharam Facility
Cohance Lifesciences has received a formal Warning Letter from the USFDA regarding its Finished Dosage Formulations facility (FDF Unit-I) in Nacharam, Hyderabad. This follows an inspection conducted in August 2025 and a previous classification of the site as Official Action Indicated (OAI). Management has clarified that the financial impact is limited, as US revenues from this facility contributed less than 2% of consolidated revenues in FY2025. The company is currently working with the regulator to address compliance concerns and resolve the issues at the earliest.
Key Highlights
USFDA issued a Warning Letter for the Nacharam formulation facility following an August 2025 inspection.
The facility's US-linked revenue accounted for less than 2% of consolidated revenues in FY2025.
Related EBITDA contribution from the facility was less than 1% of the total in FY2025.
The site was previously classified as Official Action Indicated (OAI) prior to this Warning Letter.
Company is engaging with the USFDA to remediate the observations and ensure regulatory compliance.
💼 Action for Investors
Investors should note that while the immediate financial impact is minimal, a Warning Letter typically halts new product approvals from the affected site. Monitor the company's progress in resolving the USFDA observations to ensure no further escalation or spillover to other facilities.
Cohance Lifesciences Appoints Sunil Kumar Singh as Chief Quality Officer
Cohance Lifesciences has appointed Mr. Sunil Kumar Singh as Chief Quality Officer and Senior Management Personnel, effective January 19, 2026. Mr. Singh brings over 35 years of extensive experience in pharmaceutical quality management across APIs, formulations, and CDMO sectors. He previously served as the Global Head of Quality for the PSAI Business at Dr. Reddy’s Laboratories and held senior roles at Mylan and Cipla. This strategic hire is intended to strengthen the company's regulatory compliance and quality governance frameworks.
Key Highlights
Mr. Sunil Kumar Singh appointed as Chief Quality Officer and Senior Management Personnel effective January 19, 2026.
Brings over 35 years of leadership experience in pharmaceutical quality, including APIs and CDMO ecosystems.
Former Global Head of Quality for PSAI Business and Global Head of Internal Audit at Dr. Reddy’s Laboratories.
Extensive career history with leading pharmaceutical firms including Mylan, Zydus, Glenmark, and Cipla.
Focus will be on science-driven quality transformation, digitalization, and proactive risk governance.
💼 Action for Investors
Investors should view this as a positive development for the company's operational stability and regulatory standing. No immediate action is required, but the appointment of a high-caliber veteran from Dr. Reddy's strengthens the management team.
Cohance Lifesciences Seeks Approval for Himanshu Agarwal as WTD and CFO for 5-Year Term
Cohance Lifesciences Limited has issued a postal ballot notice to seek shareholder approval for the appointment of Mr. Himanshu Agarwal as a Whole-time Director and Chief Financial Officer. The proposed appointment is for a five-year tenure, effective from October 29, 2025, to October 28, 2030. Shareholders can participate in the remote e-voting process which commences on December 24, 2025, and concludes on January 22, 2026. This move aims to formalize his position after his initial appointment as an Additional Director by the Board.
Key Highlights
Appointment of Mr. Himanshu Agarwal as Whole-time Director and CFO for a period of 5 years.
The term of appointment is set from October 29, 2025, through October 28, 2030.
Remote e-voting period is scheduled from December 24, 2025 (9:00 AM) to January 22, 2026 (5:00 PM).
The cut-off date for determining shareholder eligibility for voting was December 19, 2025.
Final voting results are expected to be declared on or before January 23, 2026.
💼 Action for Investors
Investors should take note of the leadership continuity in the finance function and may participate in the e-voting process as per the provided schedule. This is a routine regulatory requirement for confirming executive appointments.
Cohance Lifesciences Resubmits Financial Results for Q2 2026
Cohance Lifesciences Limited has resubmitted its Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2025, in machine-readable form, as per NSE requirements. The original results were submitted on November 12, 2025, and there are no changes in the financials. Standalone revenue from operations for the quarter ended September 30, 2025, was ₹497.79 crore, and net profit for the period was ₹94.19 crore. Consolidated revenue from operations for the quarter ended September 30, 2025, was ₹555.57 crore, with a net profit of ₹66.39 crore.
Key Highlights
Standalone revenue from operations for Q2 2026: ₹497.79 crore
Standalone net profit for Q2 2026: ₹94.19 crore
Consolidated revenue from operations for Q2 2026: ₹555.57 crore
Consolidated net profit for Q2 2026: ₹66.39 crore
Total standalone income for half year ended September 30, 2025: ₹1020.77 crore
💼 Action for Investors
Review the detailed financial results for Cohance Lifesciences to assess the company's performance and consider how it aligns with your investment strategy. Monitor future announcements for any significant changes in financial performance.
Cohance Lifesciences Receives Credit Rating of IND AA/Stable/IND A1+
India Ratings & Research has assigned a credit rating of IND AA/Stable/IND A1+ to Cohance Lifesciences Limited's bank loan facilities. The rating applies to bank loan facilities totaling ₹6,850 million. This rating indicates a stable outlook for the company's ability to meet its financial obligations. Investors should note this positive credit rating as an indicator of the company's financial health.
Key Highlights
Bank loan facilities rated at IND AA/Stable/IND A1+
Total size of bank loan facilities rated is ₹6,850 million
Citibank N.A. term loan rated IND AA/Stable with an outstanding amount of ₹343.00 million
Axis Bank Limited term loan rated IND AA/Stable with an outstanding amount of ₹833.00 million
State Bank of India fund-based working capital limits rated IND AA/Stable/IND A1+ with an outstanding amount of ₹1300.00 million
💼 Action for Investors
Investors can view this credit rating as a positive signal regarding Cohance Lifesciences' financial stability. Monitor future credit rating updates for any changes that may affect the company's outlook.